Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV16-E7 A*02:01 TCR-T
- Development stage
- Unknown
- Lead developer
- Anocca
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HPV16-E7 A*02:01 TCR-T is an autologous T-cell receptor-engineered T-cell (TCR-T) therapy being developed by Anocca for the treatment of HPV16-positive cancers. The therapy consists of a patient's own T cells that have been genetically modified to express a specific T-cell receptor (TCR) capable of recognizing the HPV16 E7 oncoprotein peptide when presented by the HLA-A*02:01 allele. The E7 protein is a viral oncoprotein essential for the maintenance of the malignant phenotype in HPV-driven cancers, such as cervical and head and neck squamous cell carcinomas. By targeting this intracellular antigen, the engineered T cells can selectively identify and eliminate tumor cells. The therapy is currently being evaluated in Phase 1 clinical trials for patients with HPV16-positive solid tumors who express the HLA-A*02:01 allele.
- Other names
- Anocca HPV16 E7 TCR-THPV16 E7 A*02:01 TCR-T cell therapyAnocca-HPV16 E7 (presented on HLA-A*02:01)-TCR-T cell therapy
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on HPV16-E7 A*02:01 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV16-E7 A*02:01 TCR-T.